Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘Notch’

Washington Monument

After exploring a mechanistic approach and a tumour type as part of our AACR annual meeting coverage, in our third preview today we turn to look at a novel target.

This particular target hasn’t received much attention at all but this could well change in the future as some of the compounds move into the clinic.

There are a few important questions to consider:

  • Who’s going to be first to evaluate in humans?
  • Which tumour types will be optimal?
  • Which combinations are likely to be synergistic, tolerable and effective?
  • What path to market strategies will avoid the enrollment problems now that checkpoint blockade is becoming much more ubiquitous?

This is an interesting niche that may well evolve into a competitive landscape going forward.

Subscribers can log-in below

At the European Cancer Conference (ECC 2015) held in Vienna recently, a number of promising targets emerged along with new drugs in development in several different tumour types.  Not all of them were from big Pharma – some were from up and coming young biotechs that will be worth watching out for.

Austria SchnappsIn this first part of our ‘New Drugs on the Horizon’ mini series, we chose four interesting and largely positive studies to highlight and discuss in-depth.

In the past, there were many negative trials to pick over and ponder why they didn’t quite pan out.  After all, it’s relatively easy to be an armchair critic and hindsight is a wonderful thing.

Picking only four from the many promising choices of trials presented this year available turned out to be quite hard given there were many that caught our attention – a bit like choosing only one of four out of the many schnaps to sample locally!

Today’s review looks at four very different drugs and approaches in early development from Pfizer, Stemcentrx and Ignyta – they include encouraging early data on both small molecule tyrosine kinase inhibitors (TKIs), as well as antibody drug conjugates (ADCs).

To learn more insights on this intriguing topic, subscribers can log-in or you can purchase access to BSB Premium Content. 

error: Content is protected !!